Physician profile
Robert C Frazier
NPI 1821051947
$5,570.94
in general payments reported to CMS, 2019-2025
45 companies · $787 in 2025
The $787 reported for 2025 was more than what 81% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,343 · 2020: $188 · 2021: $259 · 2022: $576 · 2023: $1,479 · 2024: $939 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,205.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $686.91 | 2021-2023 | Prolaris |
| Raysearch Laboratories Ab (Publ) | $485.00 | 2019 | |
| Novocure INC. | $452.55 | 2019-2025 | Optune, Optune Gio |
| Astrazeneca Pharmaceuticals LP | $421.27 | 2019-2025 | Imfinzi, Tagrisso, Calquence |
| Novartis Pharmaceuticals Corporation | $381.88 | 2019-2025 | |
| Emd Serono, INC. | $299.79 | 2019-2025 | Bavencio, Tepmetko |
| Gt Medical Technologies, INC | $283.87 | 2023-2025 | Gammatile, Gammatile |
| Merck Sharp & Dohme LLC | $275.15 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Sumitomo Pharma America, INC. | $206.67 | 2023-2025 | Orgovyx |
| Accuray Incorporated | $200.47 | 2019-2025 | Tomo Therapy System |
| Regeneron Healthcare Solutions, INC. | $163.58 | 2022-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $152.85 | 2019-2024 | |
| Eisai INC. | $141.60 | 2023-2025 | |
| Abbvie INC. | $112.13 | 2019-2023 | |
| Elekta, INC. | $109.91 | 2019-2023 | Elekta Unity |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $106.49 | 2019-2023 | Lumakras |
| Mevion_medical_systems_inc | $82.73 | 2022-2023 | Pts250 |
| Seagen INC. | $80.53 | 2020-2023 | Tukysa, Padcev |
| Genzyme Corporation | $76.96 | 2020-2022 | |
| Beigene USA, INC. | $71.12 | 2024-2025 | Tevimbra, Brukinsa |
| Daiichi Sankyo INC. | $66.01 | 2024-2025 | Enhertu |
| Teleflex LLC | $64.34 | 2024-2025 | Barrigel |
| Janssen Biotech, INC. | $55.88 | 2019-2025 | Rybrevant, Talvey, Tecvayli |
| Karl Storz Endoscopy-America | $52.98 | 2019 | |
| Kyowa Kirin, INC. | $52.91 | 2019-2023 | Poteligeo |
| Takeda Pharmaceuticals U.S.A., INC. | $42.31 | 2024-2025 | Iclusig |
| Tactile Systems Technology INC | $41.00 | 2019-2025 | Nimbl, Flexitouch Plus |
| Beone Medicines USA, INC. | $39.19 | 2025 | Brukinsa, Tevimbra |
| Boston Scientific Corporation | $37.80 | 2024-2025 | Spaceoar Vue System - 10ml |
| Celgene Corporation | $33.78 | 2021-2023 | Pomalyst |
| Glaxosmithkline, LLC. | $33.35 | 2020-2022 | |
| Taiho Oncology, INC. | $29.27 | 2022-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $25.96 | 2019-2023 | Imbruvica |
| Genentech USA, INC. | $25.00 | 2024 | Columvi, Lunsumio, Polivy |
| Immunogen, INC. | $22.05 | 2023 | Elahere |
| Amag Pharmaceuticals, INC. | $18.93 | 2021 | |
| Kite Pharma, INC. | $18.39 | 2020 | |
| Mirati Therapeutics, INC. | $18.29 | 2023 | Krazati |
| Exelixis INC. | $18.01 | 2023 | Cabometyx |
| Palette Life Sciences, INC. | $16.35 | 2022 | |
| Epizyme, INC. | $14.39 | 2022 | |
| Mission Pharmacal Company | $13.87 | 2019 | |
| Puma Biotechnology, INC. | $13.53 | 2021 | |
| Rigel Pharmaceuticals, INC. | $13.09 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Frazier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.